What certifications or standards apply to elemental analysis labs?

Elemental analysis labs are subject to a layered set of certifications and standards depending on their sector, application, and the markets they serve. The most commonly applicable frameworks include ISO/IEC 17025 laboratory accreditation, Good Manufacturing Practice (GMP), Good Laboratory Practice (GLP), and sector-specific guidelines such as ICH Q3D for pharmaceutical elemental impurities. Understanding which standards apply to your lab is essential for maintaining compliance, protecting data integrity, and producing results that hold up under regulatory scrutiny. The sections below address the most frequently asked questions on this topic.

Which regulatory frameworks govern elemental analysis results?

Elemental analysis results are governed by a combination of international accreditation standards, sector-specific regulatory requirements, and method-level validation guidelines. The applicable frameworks depend on the industry: pharmaceutical labs face different obligations than environmental testing labs or food quality control facilities. In practice, most regulated labs operate under more than one overlapping framework at the same time.

The most relevant regulatory frameworks for elemental analysis include:

  • ISO/IEC 17025 – the international standard for testing and calibration laboratory competence
  • GMP (Good Manufacturing Practice) – mandatory in pharmaceutical and food production environments
  • GLP (Good Laboratory Practice) – applied in non-clinical safety studies and research labs
  • ICH Q3D – a guideline for elemental impurities in pharmaceutical products
  • 21 CFR Part 11 – the US FDA regulation governing electronic records and signatures in regulated labs
  • Environmental standards – such as EN ISO methods for water and soil analysis, relevant to environmental testing labs

For labs operating in the Benelux, these frameworks are typically enforced or referenced by national competent authorities, sector regulators, and customers who require third-party accreditation before accepting analytical data.

What does ISO/IEC 17025 accreditation mean for an elemental analysis lab?

ISO/IEC 17025 accreditation means that a laboratory has been formally assessed by an independent accreditation body and confirmed to be technically competent and capable of producing valid, reproducible results. For an elemental analysis lab, this covers the entire measurement process: from sample preparation and instrument calibration through data reporting and uncertainty estimation.

Achieving and maintaining ISO/IEC 17025 accreditation requires the lab to demonstrate competence in specific analytical methods, maintain documented quality management procedures, and participate in proficiency testing schemes. Instruments must be calibrated with traceable reference materials, and measurement uncertainty must be evaluated and reported for each method in scope.

For labs in the Benelux, accreditation is typically granted by RvA (the Dutch Accreditation Council) in the Netherlands or BELAC in Belgium. Accreditation signals to customers, regulators, and procurement stakeholders that results from the lab are technically reliable and internationally recognized.

How do GMP and GLP requirements apply to elemental analysis?

GMP and GLP requirements apply to elemental analysis by setting expectations for how instruments are qualified, how methods are validated, how data are recorded, and how results are reviewed and approved. Both frameworks treat the analytical instrument as a critical piece of equipment that must be installed, operated, and maintained according to documented procedures.

Under GMP, elemental analysis instruments used in pharmaceutical manufacturing or quality control must undergo Installation Qualification (IQ) and Operational Qualification (OQ) before use. Analytical methods must be validated, and any changes to instruments or procedures must go through a formal change control process. Data integrity requirements mean that raw data must be retained, traceable, and protected from unauthorized alteration.

GLP applies primarily to non-clinical laboratory studies conducted to support regulatory submissions. In this context, elemental analysis methods must be documented in Standard Operating Procedures (SOPs), and the lab must maintain records that allow a full reconstruction of any study. Both GMP and GLP environments increasingly require compliance with 21 CFR Part 11 or equivalent standards for electronic records, which affects how instrument software is configured and audited.

What is ICH Q3D and which labs need to comply with it?

ICH Q3D is an international guideline developed by the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. It establishes a risk-based framework for controlling elemental impurities in pharmaceutical drug products. Labs that test finished pharmaceutical products, active pharmaceutical ingredients (APIs), or excipients for elemental impurities need to comply with ICH Q3D requirements.

The guideline identifies a defined set of elements that must be assessed and, where necessary, controlled. It requires pharmaceutical companies to conduct a risk assessment of all potential sources of elemental contamination across the manufacturing process, including raw materials, equipment, and the manufacturing environment. Analytical methods used to measure these elements must be validated to demonstrate that they are fit for purpose within the ICH Q3D framework.

Compliance with ICH Q3D is required for new marketing authorization applications in major regulatory jurisdictions, and it is increasingly expected for existing products as well. For exact permitted daily exposure values and classification of specific elements, consult the ICH Q3D guideline directly or the applicable pharmacopeia for your market.

What method validation requirements apply to elemental analysis techniques?

Method validation requirements for elemental analysis techniques are defined by the regulatory framework under which the lab operates, but several core performance parameters apply across all regulated contexts. A validated elemental analysis method must demonstrate that it reliably measures what it is intended to measure, at the concentration levels relevant to the application, with acceptable precision and accuracy.

The key validation parameters typically required are:

  1. Specificity and selectivity – confirming the method measures the target element without interference from the matrix
  2. Linearity – demonstrating a proportional response across the relevant concentration range
  3. Accuracy – verifying agreement between measured and reference values using certified reference materials
  4. Precision – assessing repeatability (within-run) and intermediate precision (between-run or between-analyst)
  5. Limit of Detection (LOD) and Limit of Quantification (LOQ) – establishing the lowest reliably measurable concentrations
  6. Robustness – testing the method’s resilience to small, deliberate variations in operating conditions

The specific validation requirements and acceptance criteria are defined by the applicable guideline, whether that is ICH Q2(R2) for pharmaceutical methods, ISO/IEC 17025 for accredited testing labs, or sector-specific standards for food or environmental analysis. Validation documentation must be retained and made available during audits or regulatory inspections.

How can labs stay compliant as standards and regulations evolve?

Labs can stay compliant as standards evolve by building a structured approach to regulatory monitoring, instrument qualification, and staff training into their quality management system. Compliance is not a one-time achievement but an ongoing process that requires regular review of applicable standards, periodic revalidation of methods, and documented responses to regulatory changes.

Practical steps that support ongoing compliance include:

  • Assigning responsibility for regulatory monitoring to a named quality or compliance function within the lab
  • Scheduling periodic reviews of SOPs and method validation records against current guideline versions
  • Maintaining instrument qualification documentation and planning preventive maintenance in line with manufacturer recommendations and GMP/GLP expectations
  • Participating in proficiency testing schemes to benchmark analytical performance against external reference labs
  • Engaging with suppliers and instrument specialists who stay current with application-level regulatory developments

For labs in the Benelux, staying connected to sector-specific industry groups and national accreditation bodies helps ensure that regulatory updates are identified and acted on in a timely way. As guidelines like ICH Q3D continue to be updated and adopted into regional pharmacopeias, labs that have built flexibility into their quality systems are better positioned to adapt without disruption.

For exact compliance limits and threshold values, always consult the applicable pharmacopeia or the relevant regulatory guidance document for your specific market and product type.

How SciSPX supports elemental analysis compliance in the Benelux

Navigating the overlap between ISO/IEC 17025, GMP, GLP, and ICH Q3D requirements demands more than the right instrument. It requires qualified support from specialists who understand both the analytical methods and the regulatory context in which they are used.

SciSPX supports Benelux labs with:

  • IQ/OQ installations and qualifications performed by certified service engineers, in line with GMP, GLP, and 21 CFR Part 11 requirements
  • Application-level expertise from product specialists who work alongside lab technicians and researchers to ensure methods are fit for purpose
  • Validation support and calibrations that meet the documentation standards required for regulated environments
  • Preventive and corrective maintenance to keep instruments performing within specification throughout their operational life

If your lab is preparing for accreditation, updating instrument qualifications, or implementing ICH Q3D testing, contact SciSPX to discuss how our team can support your compliance requirements.

Frequently Asked Questions

What is the difference between ISO/IEC 17025 accreditation and GMP compliance — do we need both?

ISO/IEC 17025 and GMP serve different but complementary purposes: ISO/IEC 17025 is an accreditation standard that certifies a lab’s technical competence and the validity of its measurement results, while GMP is a regulatory requirement that governs the entire manufacturing and quality control process in pharmaceutical and food environments. Many regulated labs — particularly those performing quality control testing in pharmaceutical manufacturing — are required to meet both simultaneously. In practice, ISO/IEC 17025 accreditation can strengthen a GMP-compliant lab’s credibility, but the two frameworks have distinct documentation, qualification, and audit requirements that must each be addressed independently.

How do we know which elements we are required to test for under ICH Q3D?

ICH Q3D classifies elements into three categories based on their toxicological risk and likelihood of occurrence: Class 1 (high toxicity, e.g. arsenic, cadmium, lead, mercury), Class 2 (moderate toxicity, subdivided by route of administration), and Class 3 (low toxicity). Your obligation to test for specific elements is determined by a formal risk assessment that considers all potential contamination sources across your manufacturing process, including raw materials, excipients, equipment, and the production environment. Elements that cannot be ruled out as potential contaminants through the risk assessment must then be measured using validated analytical methods. The ICH Q3D guideline itself and the relevant pharmacopeia chapters — such as USP u003c232u003e/u003c233u003e or Ph. Eur. 5.20 — provide the permitted daily exposure (PDE) values and method requirements for each element.

What are the most common mistakes labs make during elemental analysis method validation?

One of the most frequent mistakes is validating a method under idealized laboratory conditions without adequately testing robustness — meaning the method has not been challenged against realistic variations in sample matrices, reagent lots, or instrument operating conditions. Another common gap is failing to establish LOD and LOQ values that are low enough to be meaningful at the concentration levels required by the applicable guideline, such as the PDEs defined in ICH Q3D. Labs also frequently underestimate the importance of matrix-matched calibration standards and certified reference materials, which are essential for demonstrating accuracy in complex sample types. Validation documentation that is incomplete or not retained in a retrievable format is a recurring finding during regulatory inspections and audits.

How often do elemental analysis instruments need to be requalified under GMP or GLP?

There is no single fixed requalification interval mandated by GMP or GLP regulations — the frequency is determined by your lab’s risk assessment, the criticality of the instrument, and the manufacturer’s recommendations. In practice, most GMP environments require an annual performance qualification (PQ) review as a minimum, with additional requalification triggered by events such as instrument relocation, major repairs, software upgrades, or significant changes to the method scope. GLP environments follow similar logic, with requalification requirements documented in the lab’s SOPs. Preventive maintenance records, calibration certificates, and any corrective actions must be retained as part of the instrument’s qualification history and made available during inspections.

Can a lab use a single validated method for multiple sample types, or does each matrix require separate validation?

In most regulated frameworks, each distinct sample matrix requires its own validation data, or at minimum a documented matrix extension study, because the physical and chemical composition of the matrix directly affects method performance parameters such as specificity, accuracy, and LOQ. A method validated for a simple aqueous pharmaceutical solution, for example, cannot automatically be assumed to perform equivalently on a complex solid dosage form or a biological matrix without supporting data. Under ICH Q2(R2) and ISO/IEC 17025, the extent of additional validation required for a new matrix depends on how similar it is to the originally validated matrix — a risk-based justification supported by experimental data is typically expected. Consulting the applicable guideline and your accreditation body’s expectations before extending a method to a new matrix is strongly recommended.

What should a lab do if an elemental analysis result exceeds a regulatory limit or specification?

An out-of-specification (OOS) or out-of-limit result must be handled through a formal investigation process — never simply repeated without documented justification. The first step is a phase one laboratory investigation to rule out assignable causes such as sample preparation errors, instrument malfunction, contamination, or calculation mistakes. If no laboratory error is identified, the result is confirmed as a genuine OOS finding and escalated to a phase two investigation involving a broader review of the batch, the manufacturing process, and raw material sources. Under GMP, all steps of the OOS investigation must be documented, and the outcome — including any corrective and preventive actions (CAPAs) — must be retained as part of the batch record. Regulatory guidance documents such as FDA’s 2006 OOS guidance provide a detailed framework for conducting these investigations in pharmaceutical environments.

How does 21 CFR Part 11 affect the software and data management systems used in elemental analysis labs?

21 CFR Part 11 requires that electronic records and electronic signatures used in regulated environments meet specific technical and procedural controls to ensure data integrity, traceability, and protection against unauthorized alteration. For elemental analysis labs, this means that instrument software used to acquire, process, and store analytical data must support audit trails, role-based access controls, and secure, time-stamped records that cannot be deleted or overwritten without a traceable record of the change. Labs must validate their software systems to confirm that these controls function as intended, and they must maintain documentation of system validation, user access management, and any changes to software configuration. When selecting or upgrading instruments, confirming that the instrument software is 21 CFR Part 11-compliant — and that the vendor can provide the necessary validation support documentation — is an important step in the procurement process.

Related Articles

This content was generated with the help of AI and it may contain mistakes

Contact our Xperts

Prefer to give us a call?

The Netherlands
+31 (0)294 280 450

Belgium & Luxembourg
+32 (02)2 334 22 70